Stemline Therapeutics (STML) Misses Q1 EPS by 10c, Revenues Beat

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.73), $0.10 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $5.05 million versus the consensus estimate of $2.36 million.

“Since ELZONRIS became commercially available in January, we have been very pleased with the progress we have made executing our launch plan,” stated Robert Francomano, SVP and Global Head of Commercial. “Our entire organization is working hard to ensure patients with BPDCN have access to ELZONRIS. Although still early, we believe the launch is progressing extremely well and remain poised for a very successful 2019 and beyond.”

Ivan Bergstein, M.D., CEO of Stemline Therapeutics, commented “We have built a solid foundation for growth, driven by our launch of ELZONRIS for patients with BPDCN. We are executing our commercial plan, including pursuing ongoing efforts to unlock additional value from ELZONRIS in other indications as well as from our entire pipeline, all with the goal of improving the lives of patients with cancer around the world.”

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c